Tiffanie McDowell
Areas of Focus
Overview
Tiffanie McDowell is a partner in Crowell & Moring's Orange County office, where she practices in the firm's Antitrust and Competition Group and Health Care groups. Her practice focuses primarily on complex antitrust litigation, pharmaceutical advertising, pricing and access issues, and health care recovery.
Career & Education
- University of Missouri, B.S., cum laude, political science, 2006
- University of Missouri, B.A., cum laude, international studies, 2006
- University of Missouri, B.B.A., cum laude, international business, 2006
- University of San Diego School of Law, J.D., Academic Scholarship, cum laude, 2012
- University of San Diego School of Law, LL.M., Dean's Academic Scholarship, cum laude, taxation, 2014
- California
Tiffanie's Insights
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies.
Client Alert | 5 min read | 04.07.26
Weight-Loss Drug Coverage Obligations: A Litigation and Regulatory Update
Speaking Engagement | 03.04.26
“Navigating Challenges in the Pharmaceutical Antitrust Landscape,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
Speaking Engagement | 03.04.26
“Partnering to Maximize and Regularize Returns,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
Insights
Speaking Engagement | 03.04.26
Speaking Engagement | 03.04.26
Tripped at Customs: EU Seizures of Indian Generic Pharmaceutical Drugs in Transit
|08.19.15
Practitioner Treatise on International Business Vol. 2, Ralph Folsom ed.
“Navigating Challenges in the Pharmaceutical Antitrust Landscape,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
|03.04.26
“Partnering to Maximize and Regularize Returns,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
|03.04.26
Industries
Tiffanie's Insights
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies.
Client Alert | 5 min read | 04.07.26
Weight-Loss Drug Coverage Obligations: A Litigation and Regulatory Update
Speaking Engagement | 03.04.26
“Navigating Challenges in the Pharmaceutical Antitrust Landscape,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
Speaking Engagement | 03.04.26
“Partnering to Maximize and Regularize Returns,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
